Startup Story: Kyntox Biotech, Revolutionizing the healthcare through passive immunotherapy

We are a growing company trying to overcome the hurdles in healthcare industry. We believe that with our expertise on IgY antibody technology, we can definitely improve the quality of life and save many more lives from diseases caused by various microbials. Our unique approach and knowledge base enable the creation of immune health solutions that address a range of needs related to the health of humans and animals.

Antimicrobials 

Many therapeutic approaches are available to address the pathogens which includes, probiotics, antibiotics, bacteriophages and others, but safety and antibiotic resistance is the major concern. To address these limitations, Kyntox Biotech is using avian (IgY) antibody technology that is safe and effective against specific and narrow targeted bacteria/ fungi/viruses. Being polyclonal, our technology prevents the generation of resistance to therapy, unlike any antibiotics/small molecules for long term dosing.

IgY based Therapeutics: For selective removal of Pathogens


Technology involves administration of designed antigen/part of targeted pathogen to chicken and
allow the bird to develop specific immunity against the targeted. The antibody (IgY) developed against
the target will be purified from the egg yolk and evaluated for its capability to neutralize the targeted
pathogen’s activity in vitro/ in vivo before formulating into a product. 

  •  Adaptable Targeting: IgY Technology has the ability to produce pathogen-specific neutralization capabilities against viruses, bacteria, fungi, endotoxins, and human secreted immune modulators. 

Milestone of KYNTOX BIOTECH

  • Company was incorporated in the year 2018 with the support from DBT-BIRAC -BIG Grant
  • Snakebite – Completed proof of concept study in animal model for a developing a snake specific antivenom therapy.
  • Company was one of ELEVATE award winners from Government of Karnataka that led to the development of proof of concept for Snake Venom Diagnostic Kit (SVDK).
  • During COVID pandemic, Kyntox Biotech had made multiple collaborations with global Biotech companies and developed an antibody based oral drink to prevent the COVID infections and successfully launched the product in Europe.
  • At present, Kyntox Biotech is exploring its potential in addressing some of the neurodegenerative diseases like Alzheimer’s and some of the gastrointestinal diseases like bloating, using our platform technology.
  • Animal health – WSSV is one of the major diseases in aquaculture. Kyntox Biotech in collaboration with other potential animal health company and developed a proof of concept in preventing WSSV infections in shrimp cultivation.
  • Targets identified and provisional patents are filed for lead programs in Snakebite management, WSSV and incorporation of IgY in various feed formulations. 

Lead Programs at KYNTOX BIOTECH

  • Alzheimer’s:
    • Alzheimer's disease is the most common type of dementia. It is a progressive disease beginning with mild memory loss. 
    • Alzheimer's disease is thought to be caused by the abnormal build-up of proteins in and around brain cells. One of the proteins involved is called amyloid, deposits of which form plaques around brain cells. 
    • Kyntox Biotech has identified the potential targets and establishing the proof of concept to prevent the accumulation of amyloids.
  • Ulcerative Colitis
    • Ulcerative colitis is a chronic inflammatory bowel disease (IBD) in which abnormal reactions of the immune system cause inflammation and ulcers on the inner lining of your large intestine. 
    • Kyntox has identified the pathogens associated with Ulcerative colitis and establishing the proof of concept in vivo.


KYNTOX EXECUTIVE TEAM

Gopi Kadiyala M.Tech, PhD, Founder & CEO – Biotechnologist
with 15 + year experience in Research & Development and IgY
antibody technology.

Swetha Kadiyala MBBS, Co-founder –10+ years of
experience in medical field and responsible as Chief
Medical Officer at Kyntox.

Satish Chandran, PhD, – Scientific Advisor -Serial entrepreneur
with 25 + year leadership positions. Notable positions include
co-founder and CEO of Somahlution, CTO Pfizer BioTx division,
and cofounder of Nucleonics one of the first RNAi companies.

Uday Saxena PhD – Scientific Advisor – With 30+ years
experience in drug discovery, Co-Founder, -Reagene
Biosciences Pvt Ltd. Few Past Associations; Pfizer USA
(Lipitor/Atorvastatin discovery team), VP of R&D at
AtheroGenics Inc ,Atlanta,

Amit Chakraborti – Director Finance -30+ year experience in
Finance and Business Strategy

Naveen Reddy, QA – 15+ years operational experience
with Biopharma companies in Quality Assurance division.

Contact: Gopi Kadiyala; gopi.kadiyala@kyntoxbiotech.com; +91-99522 22609

Comments

Post a Comment

Popular posts from this blog

Startup Story: StrideAIde

Image
 The startup scene in India has been seeing tremendous activity in the last few years and with the emergence of Artificial intelligence , it has only lead to a faster growth in people trying to use AI in giving solutions to everyday problems. The startup scene in India has been seeing tremendous activity in the last few years and with the emergence of Artificial intelligence , it has only lead to a faster growth in people trying to use AI in giving solutions to everyday problems. StrideAIde was an offshoot of collaborative research between IISC & KIER. The scientists from IISC lead by Dr.Ananthasuresh from the mechanical engineering department and doctors from KIER lead by Dr.Belehalli Pavan from the department of Podiatry where working on giving solutions to diabetic population with diabetic foot wounds. After their first product – “Dynamic self offloading foot insoles” showed amazing field results , it was decided to take this collaboration a step further and include Artifici...
Read more

Mobility and Health

Health on the Move: How Urban Mobility Shapes Our Well-being Our daily commutes and the way we navigate our cities do far more than just get us from one place to another. Urban mobility systems have a profound, often overlooked, impact on our public health. In a rapidly urbanizing world, understanding this critical intersection is key to building healthier, more livable cities. The Unseen Costs of Unsustainable Mobility When urban mobility prioritizes private vehicles and extensive road networks, the consequences for public health can be severe: • Air Pollution: Idling cars and heavy traffic lead to increased emissions of harmful pollutants,contributing to respiratory illnesses, cardiovascular diseases, and even premature deaths. These airborne toxins disproportionately affect vulnerable populations living near busy roads. • Physical Inactivity: A car-dependent urban design discourages walking and cycling, leading to more sedentary lifestyles. This, in turn, fuels the rise of no...
Read more

Pheromones in Insects

Image
( Image Courtesy: ©kozorog | AdobeStock) Definition of pheromones: Pheromones are chemicals produced as messengers that affect the behavior of other individuals of insects or other animals. They are usually wind borne but may be placed on soil, vegetation or various items. Tom Eisner, a foremost authority in the science of chemical use by insects, claims that each species of insect relies on some one hundred chemicals in its life, to engage in such routine activities as finding food and mates, aggregating to take advantage of food resources, protecting sites of oviposition, and escaping predation. It has been found that pheromones may convey different signals when presented in combinations or concentrations. Pheromones differ from sight or sound signals in a number of ways. They travel slowly, do not fade quickly, and are effective over a long range. Sound and sight receptors are not needed for pheromone detection, and pheromone direction is not limited to straight lines. Exa...
Read more